113293-71-3

Basic information

• Product Name: (6-AMINO-3-PYRIDINYL)METHANOL
• Synonyms: 6-AMINO-3-HYDROXYMETHYLPYRIDINE;(6-AMINO-3-PYRIDINYL)METHANOL;(6-AMINO-PYRIDIN-3-YL)-METHANOL;2-Amino-5-(hydroxymethyl)pyridine;2-Amino-5-pyridinemethanol;2-Amino-5-(hydroxymethyl)pyridine 97%;3-Pyridinemethanol,6-amino-(9CI);2-AMINO-5-PYRIDINEMETHANOL(2-AMINO-5-HYDROXYMETHYLPYRIDINE)
• CAS NO: 113293-71-3
• Molecular Formula: C6H8N2O
• Molecular Weight: 124.14
• Product Categories: PYRIDINE;pharmacetical;Furans
• Mol File: 113293-71-3.mol

Chemical Properties

• Melting Point: 120 °C
• Boiling Point: 320.211 °C at 760 mmHg
• Flash Point: 147.459 °C
• Appearance: /
• Density: 1.257 g/cm³
• Vapor Pressure: 0.000134mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 13.61±0.10(Predicted)
• Water Solubility: Sparingly soluble in water.(0.26 g/L) (25°C),
• CAS DataBase Reference: (6-AMINO-3-PYRIDINYL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (6-AMINO-3-PYRIDINYL)METHANOL(113293-71-3)
• EPA Substance Registry System: (6-AMINO-3-PYRIDINYL)METHANOL(113293-71-3)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38-20/21/22
• Safety Statements: 22-26-36/37/39
• RIDADR: 2811
• Hazardous Substances Data: 113293-71-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(6-AMINO-3-PYRIDINYL)METHANOL is used as a pharmaceutical intermediate for the synthesis of benzoylthiophenes. These benzoylthiophenes are allosteric enhancers of agonist activity at the A1 adenosine receptor, playing a crucial role in the development of new drugs targeting this receptor.
Used in Drug Development:
(6-AMINO-3-PYRIDINYL)METHANOL is used in drug development as a key component in the synthesis of benzoylthiophenes. These compounds have the potential to modulate the activity of the A1 adenosine receptor, which is involved in various physiological processes, including cardiovascular function, neuroprotection, and immune response. By enhancing the activity of agonists at this receptor, benzoylthiophenes may contribute to the development of novel therapeutic agents for a range of conditions.

InChI:InChI=1/C6H8N2O/c7-6-2-1-5(4-9)3-8-6/h1-3,9H,4H2,(H2,7,8)

Upstream product

• 36052-24-1 methyl 6-aminonicotinoate 
• 3167-49-5 6-aminonicotinic acid 
• 866561-42-4 acetic acid 6-(1,3-dioxo-1,3-dihydroisoindol-2-yl)pyridin-3-ylmethyl ester 
• 39658-41-8 ethyl-6-amino-nicotinate 
• 329-89-5 6-aminonicotinic amide 

Downstream Products

• 132213-07-1 6-(hydroxymethyl)imidazo[1,2-a]pyridine 
• 132213-03-7 imidazo<1,2-a>pyridin-6-ylmethylamine 
• 230617-81-9 2-amino-5-pyridylmethyl chloride 
• 929898-44-2 {2-[4-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-phenyl]-imidazo[1,2-a]pyridin-6-yl}-methanol 
• 1034309-74-4 5-(tert-butyldiphenylsilanyloxymethyl)pyridin-2-ylamine 
• 938461-34-8 {2-[4-(1,3-oxazol-5-yl)phenyl]imidazo[1,2-a]pyridin-6-yl}methanol 
• 1227486-25-0 [6-(tritylamino)pyridin-3-yl]methanol 
• 1227486-26-1 5-[(dimethylamino)methyl]-N-tritylpyridin-2-amine 
• 1227486-27-2 5-(methoxymethyl)-N-tritylpyridin-2-amine 
• 1018447-30-7 phenyl 5-((tert-butyldimethylsilyloxy)methyl)pyridin-2-ylcarbamate 
• 1419604-39-9 1-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methyl)-3-(5-((tert-butyldimethylsilyloxy)methyl)pyridin-2-yl)urea 
• 1419601-14-1 1-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methyl)-3-(5-(hydroxymethyl)pyridin-2-yl)urea 
• 69879-22-7 6-amino-3-pyridinecarbaldehyde 
• 1180132-17-5 5-((4-ethylpiperazin-1-yl)methyl)-6-methylpyridin-2-amine 

Relevant articles and documents

Photoswitchable Inhibitor of the Calcium Channel TRPV6

Herein we report the first photoswitchable inhibitor of Transient Receptor Potential Vanilloid 6 (TRPV6), a selective calcium channel involved in a number of diseases and in cancer progression. By surveying analogs of a previously reported TRPV6 inhibitor appended with a phenyl-diazo group, we identified a compound switching between a weak TRPV6 inhibitor in its dark, E-diazo stereoisomer (Z/E = 3:97, IC50 ? 10 μM) and a potent inhibitor as the Z-diazo stereoisomer accessible reversibly by UV irradiation at λ = 365 nm (Z/E = 3:1, IC50 = 1.7 ± 0.4 μM), thereby allowing precise spatiotemporal control of inhibition. This new tool compound should be useful to deepen our understanding of TRPV6.

The photosolvolysis of N-arylmethyladenines. Photoremovable N-arylmethyl protective groups for N-containing compounds

N-arylmethyladenines are photolyzed in water, giving adenine and the corresponding arylmethanols.The reaction is not only observed when the arylmethyl group is a metasubstituted benzyl, but also with more complex substituents like imidazopyridin-6-ylmethyl.Meta-substituted arylmethyl groups are proposed as photoremovable N-protective groups in adenine chemistry.

CRYSTAL FORM, SALT TYPE OF SUBSTITUTED 2-HYDRO-PYRAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR

A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like.

SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES

The invention relates to heterocyclic aza derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted Heterocyclic Aza Compounds

Heterocyclic aza compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also methods of using these compounds for the treatment and/or inhibition of pain and further diseases and/or disorders.

Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders.

INDOLYLMALEIMIDE DERIVATIVES

A compound of formula (I) wherein R denotes another heterocylic residue and wherein Ra, Rb, Rc, Rd and Re, are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION

To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition. The invention provides a compound represented by formula (1) : (wherein X1 represents an optionally substituted bicyclic heterocyclic group; X2 represents a hydrogen atom, a halogen atom, or a chelate-forming group; ring A represents a benzene ring or a pyridine ring; and ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.

Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors

Tumor cells extensively utilize the pentose phosphate pathway for the synthesis of ribose. Transketolase is a key enzyme in this pathway and has been suggested as a target for inhibition in the treatment of cancer. In a pharmacodynamic study, nude mice with xenografted HCT-116 tumors were dosed with 1 ('N3′-pyridyl thiamine'; 3-(6-methyl-2-amino-pyridin-3-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium chloride hydrochloride), an analog of thiamine, the co-factor of transketolase. Transketolase activity was almost completely suppressed in blood, spleen, and tumor cells, but there was little effect on the activity of the other thiamine-utilizing enzymes α-ketoglutarate dehydrogenase or glucose-6-phosphate dehydrogenase. Synthesis and SAR of transketolase inhibitors is described.